In the wake of new FDA guidance and exciting MRD partnership announcements between Grail and AstraZeneca, Amgen and Bristol Myers Squibb the liquid biopsy industry is experiencing a paradigm shift. Touted as having the potential to transform clinical practice as we know it, technical progress and mounting investment in premetastatic applications are creating huge industry-wide excitement for liquid biopsy-based screening and surveillance for novel precision drug development.

With technology maturity on the near horizon, the inaugural Liquid Biopsy Surveillance and Early Detection Summit is your only dedicated platform providing much-needed clarity on the industry's emerging assays increasingly opening the doors to novel trial design and better patient outcomes.

As drug and diagnostic developers look to realize the commercial impact of early detection and MRD while shifting pipelines from the metastatic setting, here lies your best opportunity to harness game-changing technologies to define leading stratification, surrogate endpoint, and regulatory strategies - accelerating the delivery of breakthrough therapies into the clinic.

Providing a path forward for early detection and surveillance to become a widespread patient reality, unite with 80+ Translational, Biomarker, Clinical, Regulatory, Precision Medicine, Medical Affairs and Diagnostic experts at your only forum prioritizing liquid biopsy applications for earlier intervention.

Ensure you and your team stay ahead of the curve with unmissable intelligence November!

Time: 07:30 - 16:00

Continue reading at lbx-surveillance-early-detection-summit.com

Health and Wellness

Facebook Share

Twitter Share

Linkedin Share

Email Share